常任理事

Medicine & Life Sciences

1. Pemphigus 100%
2. Esophageal Neoplasms 93%
3. Rheumatoid Arthritis 89%
4. Esophagectomy 70%
5. Japan 64%
6. Desmoglein 3 56%
7. Stomach Neoplasms 54%
8. Esophageal Squamous Cell Carcinoma 54%
9. Neoplasms 51%
10. Neoplasm Metastasis 43%
11. Therapeutics 37%
12. Methotrexate 37%
13. Safety 34%
14. Autoantibodies 34%
15. Lymph Nodes 32%
16. Survival 31%
17. Recurrence 30%
18. Immunoglobulin G 30%
19. Sentinel Lymph Node 29%
20. Desmoglein 1 28%
21. Skin 27%
22. Drug Therapy 27%
23. Liver Transplantation 27%
24. Colorectal Neoplasms 26%
25. Desmogleins 25%
26. Chemoradiotherapy 25%
27. Liver 23%
28. Serum 23%
29. Living Donors 22%
30. Cisplatin 22%
31. tocilizumab 22%
32. Gastrectomy 21%
33. Antibodies 21%
34. Fluorouracil 21%
35. Laparoscopy 20%
36. Bullous Pemphigoid 19%
37. Spine 18%
38. Lymph Node Excision 18%
39. Transplants 18%
40. Breast Neoplasms 18%
41. Pancreatic Neoplasms 17%
42. Stomach 17%
43. Thorax 17%
44. Joints 17%
45. Systemic Lupus Erythematosus 17%
46. Retrospective Studies 17%
47. baricitinib 16%
48. Placebos 16%
49. Incidence 15%
50. Postoperative Complications 15%
51. Blister 15%
52. Cohort Studies 15%
53. Coronavirus 15%
54. Gastrointestinal Neoplasms 15%
55. Adalimumab 14%
56. Antirheumatic Agents 14%
57. Ossification of Posterior Longitudinal Ligament 14%
58. Keratinocytes 14%
59. T-Lymphocytes 14%
60. Adenocarcinoma 14%
61. Immunoglobulin G4-Related Disease 13%
62. Carcinoma 13%
63. Atopic Dermatitis 13%
64. Knee 13%
65. Genes 13%
66. Spinal Cord 13%
67. Autoimmune Diseases 13%
68. Biomarkers 13%
69. Hepatocellular Carcinoma 12%
70. Esophagus 12%
71. Bone and Bones 12%
72. Antigens 12%
73. Surgical Wound Infection 12%
74. Multicenter Studies 12%
75. Prospective Studies 12%
76. Laminoplasty 12%
77. B-Lymphocytes 12%
78. Infliximab 11%
79. Anastomotic Leak 11%
80. Databases 11%
81. Docetaxel 11%
82. Spinal Cord Diseases 11%
83. Abatacept 11%
84. Systematic Reviews 11%
85. Confidence Intervals 10%
86. Pneumonia 10%
87. filaggrin 10%
88. Magnetic Resonance Imaging 10%
89. Nivolumab 10%
90. Tomography 10%
91. Phenotype 10%
92. Proteins 10%
93. Neoadjuvant Therapy 10%
94. C-Reactive Protein 10%
95. Anti-Idiotypic Antibodies 10%
96. Squamous Cell Carcinoma 10%
97. Swine 10%
98. Infections 10%
99. Mutation 10%
100. Enzyme-Linked Immunosorbent Assay 10%